Concepedia

Author

Lars Endahl

Novo Nordisk (Denmark)

Also Known As

Ida Carøe Helmark, L Endahl, L. A. Endahl, L. Endahl, Lars A Endahl, Lars A. Endahl, Lars Endahl

43

Publications

3.1K

Citations

21

H-Index

30

Concepts

All Affiliations

Novo Nordisk (Denmark)Profil Institute for Metabolic ResearchUniversity of TorontoDallas Diabetes Research CenterUniversitair Ziekenhuis Leuven
LE

About

Lars Endahl is an author at Novo Nordisk (Denmark) specializing in medicine, diabetes, and health sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

544

2

Diabetes

5

5

533

3

Health Sciences

3

3

79

4

Biostatistics

2

2

38

5

Endocrinology

2

2

52

Lars Endahl

×

21

Publications

2.7K

Citations

19

H-Index

YearCitations

Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes

Tim Heise, Leszek Nosek, Birgitte Rønn,

Diabetes

2004

618

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes

Bernard Zinman, Athena Philis‐Tsimikas, Bertrand Cariou,

Diabetes Care

2012

333

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Alan J. Garber, Allen B. King, Stefano Del Prato,

The Lancet

2012

323

A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir

Johannes Plank, Manfred Bodenlenz, Frank Sinner,

Diabetes Care

2005

272

Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetes

Oliver Klein, Jan Lynge, Lars Endahl,

Diabetes Obesity and Metabolism

2006

252

Insulin Degludec in Type 1 Diabetes

Kåre I. Birkeland, Philip Home, Ulrich Wendisch,

Diabetes Care

2011

160

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

Bernard Zinman, Greg Fulcher, Paturi Vishnupriya Rao,

The Lancet

2011

131

Superior glycaemic control with once‐daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial

Yukiko Onishi, Yasuhiro Ono, Rasmus Rabøl,

Diabetes Obesity and Metabolism

2013

93

Increasing inequality in ischaemic heart disease morbidity among employed men in Denmark 1981-1993: the need for a new preventive policy

Finn Tüchsen, Lars Endahl

International Journal of Epidemiology

1999

64

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

Leo Niskanen, Lawrence A. Leiter, Edward Franek,

European Journal of Endocrinology

2012

62

Page 1